{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T09:27:30Z","timestamp":1793784450964,"version":"4.6.1"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"36","license":[{"start":{"date-parts":[[2021,8,27]],"date-time":"2021-08-27T00:00:00Z","timestamp":1630022400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"name":"British Heart Foundation Centre of Research Excellence Grant","award":["RE\/18\/6\/34217"],"award-info":[{"award-number":["RE\/18\/6\/34217"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,9,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>The aim of this study was to examine the effect of dapagliflozin on the incidence of ventricular arrhythmias and sudden death in patients with heart failure and reduced ejection fraction (HFrEF).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>In a post hoc analysis of DAPA-HF, we examined serious adverse event reports related to ventricular arrhythmias or cardiac arrest, in addition to adjudicated sudden death. The effect of dapagliflozin, compared with placebo, on the composite of the first occurrence of any serious ventricular arrhythmia, resuscitated cardiac arrest, or sudden death was examined using Cox proportional hazards models. A serious ventricular arrhythmia was reported in 115 (2.4%) of the 4744 patients in DAPA-HF (ventricular fibrillation in 15 patients, ventricular tachycardia in 86, \u2018other\u2019 ventricular arrhythmia\/tachyarrhythmia in 12, and torsade de pointes in 2 patients). A total of 206 (41%) of the 500 cardiovascular deaths occurred suddenly. Eight patients survived resuscitation from cardiac arrest. Independent predictors of the composite outcome (first occurrence of any serious ventricular arrhythmia, resuscitated cardiac arrest or sudden death), ranked by chi-square value, were log-transformed N-terminal pro-B-type natriuretic peptide, history of ventricular arrhythmia, left ventricular ejection fraction, systolic blood pressure, history of myocardial infarction, male sex, body mass index, serum sodium concentration, non-white race, treatment with dapagliflozin, and cardiac resynchronization therapy. Of participants assigned to dapagliflozin, 140\/2373 patients (5.9%) experienced the composite outcome compared with 175\/2371 patients (7.4%) in the placebo group [hazard ratio 0.79 (95% confidence interval 0.63\u20130.99), P\u2009=\u20090.037], and the effect was consistent across each of the components of the composite outcome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Dapagliflozin reduced the risk of any serious ventricular arrhythmia, cardiac arrest, or sudden death when added to conventional therapy in patients with HFrEF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial registration<\/jats:title>\n                    <jats:p>\u2003ClinicalTrials.gov unique identifier: NCT03036124 (DAPA-HF).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eurheartj\/ehab560","type":"journal-article","created":{"date-parts":[[2021,8,3]],"date-time":"2021-08-03T07:19:09Z","timestamp":1627975149000},"page":"3727-3738","source":"Crossref","is-referenced-by-count":235,"title":["Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF"],"prefix":"10.1093","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1795-7445","authenticated-orcid":false,"given":"James P","family":"Curtain","sequence":"first","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow , Scotland, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5446-9969","authenticated-orcid":false,"given":"Kieran F","family":"Docherty","sequence":"additional","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow , Scotland, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4306-5317","authenticated-orcid":false,"given":"Pardeep S","family":"Jhund","sequence":"additional","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow , Scotland, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6333-9496","authenticated-orcid":false,"given":"Mark C","family":"Petrie","sequence":"additional","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow , Scotland, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio E","family":"Inzucchi","sequence":"additional","affiliation":[{"name":"Section of Endocrinology, Yale School of Medicine , New Haven, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6635-1466","authenticated-orcid":false,"given":"Lars","family":"K\u00f8ber","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Rigshospitalet, Copenhagen University Hospital , Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikhail N","family":"Kosiborod","sequence":"additional","affiliation":[{"name":"Saint Luke\u2019s Mid America Heart Institute, University of Missouri , Kansas City, MO, USA"},{"name":"The George Institute for Global Health, University of New South Wales , Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe A","family":"Martinez","sequence":"additional","affiliation":[{"name":"Universidad Nacional de C\u00f3rdoba , C\u00f3rdoba, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Ponikowski","sequence":"additional","affiliation":[{"name":"Center for Heart Diseases, University Hospital, Wroclaw Medical University , Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc S","family":"Sabatine","sequence":"additional","affiliation":[{"name":"TIMI Study Group, Brigham and Women's Hospital , Boston, MA, USA"},{"name":"D \u00a0 , Boston, MA, USA"},{"name":"ivision of Cardiovascular Medicine, Brigham and Women\u2019s Hospital \u00a0 , Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1315-8176","authenticated-orcid":false,"given":"Olof","family":"Bengtsson","sequence":"additional","affiliation":[{"name":"Lat \u00a0 , Gothenburg, Sweden"},{"name":"e Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca \u00a0 , Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Langkilde","sequence":"additional","affiliation":[{"name":"Lat \u00a0 , Gothenburg, Sweden"},{"name":"e Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca \u00a0 , Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikaela","family":"Sj\u00f6strand","sequence":"additional","affiliation":[{"name":"Lat \u00a0 , Gothenburg, Sweden"},{"name":"e Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca \u00a0 , Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D","family":"Solomon","sequence":"additional","affiliation":[{"name":"D \u00a0 , Boston, MA, USA"},{"name":"ivision of Cardiovascular Medicine, Brigham and Women\u2019s Hospital \u00a0 , Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6317-3975","authenticated-orcid":false,"given":"John J V","family":"McMurray","sequence":"additional","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow , Scotland, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,8,27]]},"reference":[{"key":"2022102514353904300_ehab560-B1","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"2022102514353904300_ehab560-B2","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"2022102514353904300_ehab560-B3","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","article-title":"SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials","volume":"396","author":"Zannad","year":"2020","journal-title":"Lancet"},{"key":"2022102514353904300_ehab560-B4","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"key":"2022102514353904300_ehab560-B5","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1093\/eurheartj\/ehv316","article-title":"2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the Task Force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC)","volume":"36","author":"Priori","year":"2015","journal-title":"Eur Heart J"},{"key":"2022102514353904300_ehab560-B6","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/j.jacc.2017.10.053","article-title":"2017 AHA\/ACC\/HRS Guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society","volume":"72","author":"Al-Khatib","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2022102514353904300_ehab560-B7","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1097\/HCO.0000000000000733","article-title":"Ventricular arrhythmias in heart failure with reduced ejection fraction","volume":"35","author":"Voskoboinik","year":"2020","journal-title":"Curr Opin Cardiol"},{"key":"2022102514353904300_ehab560-B8","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1093\/eurheartj\/ehz553","article-title":"What causes sudden death in patients with chronic heart failure and a reduced ejection fraction?","volume":"41","author":"Packer","year":"2020","journal-title":"Eur Heart J"},{"key":"2022102514353904300_ehab560-B9","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1136\/heartjnl-2016-310850","article-title":"Non-ischaemic cardiomyopathy, sudden death and implantable defibrillators: a review and meta-analysis","volume":"104","author":"Beggs","year":"2018","journal-title":"Heart"},{"key":"2022102514353904300_ehab560-B10","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1609758","article-title":"Declining risk of sudden death in heart failure","volume":"377","author":"Shen","year":"2017","journal-title":"N Engl J Med"},{"key":"2022102514353904300_ehab560-B11","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1016\/j.jacc.2020.10.005","article-title":"Effect of empagliflozin on hemodynamics in patients with heart failure and reduced ejection fraction","volume":"76","author":"Omar","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2022102514353904300_ehab560-B12","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ahj.2020.07.011","article-title":"Twelve weeks of treatment with empagliflozin in patients with heart failure and reduced ejection fraction: a double-blinded, randomized, and placebo-controlled trial","volume":"228","author":"Jensen","year":"2020","journal-title":"Am Heart J"},{"key":"2022102514353904300_ehab560-B13","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1001\/jamacardio.2020.6827","article-title":"Associations of empagliflozin with left ventricular volumes, mass, and function in patients with heart failure and reduced ejection fraction: a substudy of the empire HF randomized clinical trial","volume":"6","author":"Omar","year":"2021","journal-title":"JAMA Cardiol"},{"key":"2022102514353904300_ehab560-B14","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jacc.2020.11.008","article-title":"Randomized trial of empagliflozin in nondiabetic patients with heart failure and reduced ejection fraction","volume":"77","author":"Santos-Gallego","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2022102514353904300_ehab560-B15","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1161\/CIRCULATIONAHA.120.052186","article-title":"Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF)","volume":"143","author":"Lee","year":"2021","journal-title":"Circulation"},{"key":"2022102514353904300_ehab560-B16","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s12933-020-01127-z","article-title":"Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial","volume":"19","author":"Shimizu","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"2022102514353904300_ehab560-B17","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1161\/CIRCULATIONAHA.120.045691","article-title":"Empagliflozin in heart failure: diuretic and cardiorenal effects","volume":"142","author":"Griffin","year":"2020","journal-title":"Circulation"},{"key":"2022102514353904300_ehab560-B18","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1161\/CIRCULATIONAHA.121.053350","article-title":"Cardiac late sodium channel current is a molecular target for the sodium\/glucose cotransporter 2 inhibitor empagliflozin","volume":"143","author":"Philippaert","year":"2021","journal-title":"Circulation"},{"key":"2022102514353904300_ehab560-B19","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1002\/ehf2.13024","article-title":"Empagliflozin inhibits Na+\/H+ exchanger activity in human atrial cardiomyocytes","volume":"7","author":"Trum","year":"2020","journal-title":"ESC Heart Fail"},{"key":"2022102514353904300_ehab560-B20","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1002\/ejhf.1548","article-title":"The Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure (DAPA-HF) trial: baseline characteristics","volume":"21","author":"McMurray","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2022102514353904300_ehab560-B21","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1002\/ejhf.1432","article-title":"A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF)","volume":"21","author":"McMurray","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2022102514353904300_ehab560-B22","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"key":"2022102514353904300_ehab560-B23","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1177\/1536867X0400400212","article-title":"Splitting time-span records with categorical time-varying covariates","volume":"4","author":"Jann","year":"2004","journal-title":"Stata J"},{"key":"2022102514353904300_ehab560-B24","doi-asserted-by":"crossref","first-page":"3437","DOI":"10.1093\/eurheartj\/ehaa226","article-title":"Clinical effectiveness of primary prevention implantable cardioverter-defibrillators: results of the EU-CERT-ICD controlled multicentre cohort study","volume":"41","author":"Zabel","year":"2020","journal-title":"Eur Heart J"},{"key":"2022102514353904300_ehab560-B25","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s00392-018-1378-0","article-title":"Impact of mineralocorticoid receptor antagonists on the risk of sudden cardiac death in patients with heart failure and left-ventricular systolic dysfunction: an individual patient-level meta-analysis of three randomized-controlled trials","volume":"108","author":"Rossello","year":"2019","journal-title":"Clin Res Cardiol"},{"key":"2022102514353904300_ehab560-B26","doi-asserted-by":"crossref","first-page":"e021108","DOI":"10.1136\/bmjopen-2017-021108","article-title":"Effectiveness of drug interventions to prevent sudden cardiac death in patients with heart failure and reduced ejection fraction: an overview of systematic reviews","volume":"8","author":"Al-Gobari","year":"2018","journal-title":"BMJ Open"},{"key":"2022102514353904300_ehab560-B27","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1002\/clc.20762","article-title":"The effect of aldosterone antagonists for ventricular arrhythmia: a meta-analysis","volume":"33","author":"Wei","year":"2010","journal-title":"Clin Cardiol"},{"key":"2022102514353904300_ehab560-B28","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/S0002-8703(99)70083-9","article-title":"Metoprolol CR\/XL in patients with heart failure: a pilot study examining the tolerability, safety, and effect on left ventricular ejection fraction","volume":"138","author":"Goldstein","year":"1999","journal-title":"Am Heart J"},{"key":"2022102514353904300_ehab560-B29","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1007\/s00392-019-01440-y","article-title":"Sacubitril\/valsartan reduces ventricular arrhythmias in parallel with left ventricular reverse remodeling in heart failure with reduced ejection fraction","volume":"108","author":"Martens","year":"2019","journal-title":"Clin Res Cardiol"},{"key":"2022102514353904300_ehab560-B30","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1161\/CIRCULATIONAHA.118.034755","article-title":"Is sacubitril\/valsartan (also) an antiarrhythmic drug?","volume":"138","author":"Sarrias","year":"2018","journal-title":"Circulation"},{"key":"2022102514353904300_ehab560-B31","doi-asserted-by":"crossref","first-page":"119440","DOI":"10.1016\/j.lfs.2021.119440","article-title":"Anti-arrhythmic and inotropic effects of empagliflozin following myocardial ischemia","volume":"276","author":"Azam","year":"2021","journal-title":"Life Sci"},{"key":"2022102514353904300_ehab560-B32","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1007\/s00392-021-01888-x","article-title":"Development and external validation of prognostic models to predict sudden and pump-failure death in patients with HFrEF from PARADIGM-HF and ATMOSPHERE","volume":"110","author":"Shen","year":"2021","journal-title":"Clin Res Cardiol"},{"key":"2022102514353904300_ehab560-B33","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12933-019-0914-1","article-title":"Dapagliflozin improves left ventricular remodeling and aorta sympathetic tone in a pig model of heart failure with preserved ejection fraction","volume":"18","author":"Zhang","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"2022102514353904300_ehab560-B34","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/1475-2840-12-70","article-title":"The sodium glucose cotransporter 2 inhibitor empagliflozin does not prolong QT interval in a thorough QT (TQT) study","volume":"12","author":"Ring","year":"2013","journal-title":"Cardiovasc Diabetol"},{"key":"2022102514353904300_ehab560-B35","doi-asserted-by":"crossref","first-page":"53","DOI":"10.33963\/KP.15666","article-title":"Empagliflozin significantly attenuates sotalol-induced QTc prolongation in rats","volume":"79","author":"\u00d6zg\u00fcr Bar\u0131\u015f","year":"2021","journal-title":"Kardiol Pol"},{"key":"2022102514353904300_ehab560-B36","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1007\/s00125-017-4509-7","article-title":"Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+\/H+ exchanger, lowering of cytosolic Na+ and vasodilation","volume":"61","author":"Uthman","year":"2018","journal-title":"Diabetologia"},{"key":"2022102514353904300_ehab560-B37","article-title":"Off-target effects of SGLT2 blockers: empagliflozin does not inhibit Na+\/H+ exchanger-1 or lower [Na+]i in the heart","author":"Chung","year":"2020","journal-title":"Cardiovasc Res"},{"key":"2022102514353904300_ehab560-B38","doi-asserted-by":"crossref","first-page":"592233","DOI":"10.3389\/fcvm.2020.592233","article-title":"Empagliflozin decreases lactate generation in an NHE-1 dependent fashion and increases alpha-ketoglutarate synthesis from palmitate in type II diabetic mouse hearts","volume":"7","author":"Zhang","year":"2020","journal-title":"Front Cardiovasc Med"},{"key":"2022102514353904300_ehab560-B39","doi-asserted-by":"crossref","first-page":"5437","DOI":"10.3390\/ijms22115437","article-title":"Low-dose empagliflozin improves systolic heart function after myocardial infarction in rats: regulation of MMP9, NHE1, and SERCA2a","volume":"22","author":"Goerg","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2022102514353904300_ehab560-B40","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jacbts.2020.02.004","article-title":"Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review","volume":"5","author":"Lopaschuk","year":"2020","journal-title":"JACC Basic Transl Sci"},{"key":"2022102514353904300_ehab560-B41","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s11892-020-01359-z","article-title":"Sodium-glucose cotransporter type 2 (SGLT-2) inhibitors and ketogenesis: the good and the bad","volume":"20","author":"Ekanayake","year":"2020","journal-title":"Curr Diab Rep"},{"key":"2022102514353904300_ehab560-B42","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.5551\/jat.48009","article-title":"The effect of dapagliflozin treatment on epicardial adipose tissue volume and P-wave indices: an ad-hoc analysis of the previous randomized clinical trial","volume":"27","author":"Sato","year":"2020","journal-title":"J Atheroscler Thromb"},{"key":"2022102514353904300_ehab560-B43","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s12933-021-01293-8","article-title":"Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis","volume":"20","author":"Li","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"2022102514353904300_ehab560-B44","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.jacc.2004.09.076","article-title":"Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial","volume":"45","author":"McMurray","year":"2005","journal-title":"J Am Coll Cardiol"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/42\/36\/3727\/46625898\/ehab560.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/42\/36\/3727\/46625898\/ehab560.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T13:24:23Z","timestamp":1666704263000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/42\/36\/3727\/6358075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,27]]},"references-count":44,"journal-issue":{"issue":"36","published-online":{"date-parts":[[2021,8,27]]},"published-print":{"date-parts":[[2021,9,21]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehab560","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,9,21]]},"published":{"date-parts":[[2021,8,27]]}}}